Related Experiment Video
Updated: Jul 12, 2026
Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents
Published on: September 16, 2020
Effect of Anti-VEGF drugs on diabetic Retinopathy-Microaneurysms: A correlation study
Tianhang Li1, Zhaohui Gu2, Yueling Zhang3
1Tianhang Li, Ward of Ophthalmology 2nd Department, Baoding No.1 Central Hospital, Baoing 071000, Hebei, China.
Insights
Anti-vascular endothelial growth factor (VEGF) drugs significantly improved diabetic retinopathy (DR) outcomes. Early treatment reduced microaneurysms and improved vision, showing high clinical efficacy in patients with macular edema.
Area of Science:
- Ophthalmology
- Medical Research
- Pharmacology
Background:
- Diabetic retinopathy (DR) is a leading cause of vision loss.
- Macular edema is a common complication of DR.
- Retinal microaneurysms are a key indicator of DR severity.
Purpose of the Study:
- To evaluate the efficacy of anti-vascular endothelial growth factor (VEGF) drugs in treating diabetic retinopathy (DR).
- To assess the impact of anti-VEGF therapy on retinal microaneurysms and visual prognosis in DR patients.
Main Methods:
- A retrospective study of 120 DR patients over one year.
- Comparison between a control group (routine treatment) and an injection group (routine treatment + intravitreal anti-VEGF).
- Analysis of changes in retinal microaneurysms, best corrected visual acuity (BCVA), and central retinal thickness (CRT).
Main Results:
- The anti-VEGF injection group showed 95% total efficacy versus 80% in the control group (p<0.05).
- Significant reductions in CRT and microaneurysm count were observed in the injection group post-treatment.
- BCVA improved in the injection group, while the control group showed no significant changes.
Conclusions:
- Early intravitreal anti-VEGF therapy is highly effective for DR with macular edema.
- Treatment improves fundus lesions, reduces CRT and microaneurysms, and enhances BCVA.
- Anti-VEGF drugs offer a promising therapeutic option for managing diabetic retinopathy.
Objective:
To investigate the efficacy of anti-vascular endothelial growth factor (VEGF) drugs in diabetic retinopathy (DR)-retinal microaneurysms, and its prognosis.
Method:
This was a retrospectively study in which total of 120 patients with DR in Baoding No.1 Central Hospital from June 2020 to June 2022 were retrospectively analyzed. According to different treatment methods based on macular edema, they were divided into an injection group and a control group. The control group was treated routinely, while the injection group was additionally intravitreally injected with an anti-VEGF drug. The patients were followed up for one year, and the changes in the number of retinal microaneurysms, best corrected visual acuity (BCVA) and central retinal thickness (CRT) were compared between the two groups. The effect on retinal microaneurysms was analyzed.
Result:
After treatment for 12 months, the total efficacy of the injection group was 95.00%, which was higher than 80.00% of the control group (p< 0.05). After one, three, six and twelve months of treatment, both CRT and the number of retinal microaneurysms reduced in the injection group compared with those before treatment. After treatment for one, three, six and twelve months, BCVA showed increases in the injection group, but no obvious changes in the control group compared with that before treatment.
Conclusion:
For patients with DR complicated with macular edema, early use of anti-VEGF drugs can significantly improve the fundus lesions, reduce the CRT and number of retinal microaneurysms, and improve the BCVA of the patients, with high clinical efficacy.
More Related Videos
12:28Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies
Published on: March 12, 2022
05:14Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
01:27Diabetic Retinopathy